# Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/addition-of-an-antiangiogenic-therapy-bevacizumab-to-gemcitabine-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Marie Bréchon,Marie Dior,Johann Dréanic,Bertrand Brieau,Marie‐Anne Guillaumot,Catherine Brézault,Olivier Mir,François Goldwasser,Romain Coriat |
| Citations | 37 |
| DOI | 10.1007/s10637-017-0492-6 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2740926435 |
| PMID | 28762171 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Bertrand Brieau](https://scholariq.org/researchers/bertrand-brieau/)

## Paper journal

- [Investigational New Drugs](https://scholariq.org/journals/investigational-new-drugs/)

## Paper primary topic

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Paper topics

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.